OverviewPhase 2 Trial of Icotrokinra for Patients with Ulcerative ColitisOct 15, 2026DOI: 10.1056/nejmoa2604435Original ArticleNEJMWritten by: Maria T. Abreu, M.D.Britta Siegmund, M.D.Lindsey Surace, M.D.Ngozi Erondu, M.D., Ph.D.Minhu Chen, M.D., Ph.D.Karen Chachu, M.D., Ph.D.Edouard Louis, M.D., Ph.D.Katsuyoshi Matsuoka, M.D., Ph.D.Jimmy Limdi, M.D.Edmund Arthur, Pharm.D.Nicole Houck, B.S.Colleen Marano, Ph.D.Marion L. Vetter, M.D.Bin Zou, M.D.Joyce Zhan, Ph.D.Mary Ellen Frustaci, M.A.S.Arun K. Kannan, Ph.D.Grazyna Rydzewska, M.D., Ph.D.Edward V. Loftus, M.D.Vipul Jairath, M.B., Ch.B., D.Phil.Find these authors on RoonELDr. Edward LoftusIBD · Mayo Clinic College of MedicineFollowSummaryIn a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo.Join to read the article